Atrial Fibrillation and Heart Failure: Update 2015

Thihalolipavan, Sudarone; Morin, Daniel P.

doi:10.1016/j.pcad.2015.07.004

Cited by 50 publications

(46 citation statements)

References 114 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…At the same time, the data illustrate that CA may significantly improve cardiac function in patients with HF and AF, which corroborates the conclusions of previously published studies (15)(16)(17). Furthermore, the present study has revealed that hs-CRP, duration of AF and LAD are independent predictors of higher recurrence rates of AF in patients with HF.…”

Section: Discussionsupporting

confidence: 92%

Rosuvastatin reduces the recurrence rate following catheter ablation for atrial fibrillation in patients with heart failure

Zhao

Liu

et al. 2017

Biomedical Reports

View full text Add to dashboard Cite

Abstract. The aim of the present study was to assess whether rosuvastatin could reduce the recurrence rate of atrial fibrillation (AF) in patients with heart failure (HF) following catheter ablation (CA). A total of 107 patients with HF and AF who underwent CA of AF by endocardial mapping and radiofrequency between June 2012 and May 2014 were recruited. The patients were randomly divided into three subgroups: i) Administered with 10 mg rosuvastatin daily following ablation (group 1, n=36); ii) administered with 20 mg rosuvastatin daily following ablation (group 2, n=36); and iii) only treated with conventional treatment of HF following ablation (group 3, n=35). After the procedure, patients were followed in the outpatient clinic by interrogation of Holter monitoring. The AF recurrence rate of group 2 was low in comparison with group 1 (22.2% vs. 38.9%, P= 0.013) and group 3 (22.2% vs. 48.6%, P=0.021). In comparison with baseline, the parameters of the left ventricular ejection fraction, left atrial diameter (LAD), and the levels of N-terminal pronatriuretic peptide and hypersensitive C-reactive protein (hs-CRP) were all improved in three groups. Furthermore, multivariate analysis demonstrated that LAD [hazard ratio (HR): 1.12, 95% confidence interval (CI): 1.06-1.67, P=0.049], hs-CRP (HR: 1.37, 95% CI: 1.11-1.92, P=0.002) and duration of AF (HR: 1.14, 95% CI: 1.09-1.18, P= 0.011) were independent predictors of AF recurrence in patients with HF following CA. Therefore, the present study has demonstrated that treatment with 20 mg rosuvastatin daily following CA was able to significantly decrease the recurrence rate of AF in patients with HF, and LAD, hs-CRP, and duration of AF were independent predictors of AF recurrence in patients with HF following CA.In conclusion, the present study has also demonstrated that CA may improve cardiac function in patients with HF and AF.

show abstract

Section: Discussionsupporting

confidence: 92%

Rosuvastatin reduces the recurrence rate following catheter ablation for atrial fibrillation in patients with heart failure

Zhao

Liu

et al. 2017

Biomedical Reports

View full text Add to dashboard Cite

show abstract

“…Certain lifestyle changes addressed toward modifiable risk factors have been shown to prevent AF and decrease recurrence. These modifiable risk factors include hypertension (HTN), diabetes mellitus (DM), obstructive sleep apnea (OSA), alcohol intake, chronic strenuous exercise, caffeine intake, obesity, and CHF 11–15…”

Section: Modifiable Risk Factorsmentioning

confidence: 99%

“…The prevalence of AF in CHF patients ranges from 5% to 50%, depending on the New York Heart Association’s classification of severity of CHF 90. Their co-existence has shown to result in increased hospitalization, longer hospital stays, and increased overall mortality 15. The proposed pathogenesis for developing AF in CHF includes electrophysiologic abnormalities, such as prolonged atrial refractory period and increase in repolarization heterogeneity.…”

Section: Modifiable Risk Factorsmentioning

confidence: 99%

“…According to the AFFIRM trial, routine rhythm control does not reduce the rate of death from CV causes, as compared to the rate control strategy 15,92. Amiodarone and dofetilide are commonly used AADs for rhythm control of AF in CHF and are associated with symptom and quality of life improvement93; however, studies have been conflicting regarding their overall benefits due to proposed higher risk of ACM 94.…”

Section: Modifiable Risk Factorsmentioning

confidence: 99%

“…Targeting mechanisms involved in AF development (i.e. atrial fibrosis, cardiac remodeling) with upstream medical therapy such as ACEIs or ARBs and beta blockers has shown beneficial results in reducing incidence of AF 15. Routine follow-up with a cardiologist should be encouraged to check for medication compliance and monitor for evidence suggesting cardiac resynchronization therapy or catheter-based ablation for AF is indicated, as both have shown to preserve LV function and decrease AF burden 15,90…”

Section: Modifiable Risk Factorsmentioning

confidence: 99%

See 2 more Smart Citations

Evaluating the benefits of home-based management of atrial fibrillation: current perspectives

Sheikh

Felzer

Munir

et al. 2016

POR

View full text Add to dashboard Cite

Atrial fibrillation (AF) is the most common arrhythmia worldwide, leading to an extensive public health and economic burden. The increasing incidence and prevalence of AF is due to the advancing age of the population, structural heart disease, hypertension, diabetes, and thyroid disease. The majority of costs associated with AF have been attributed to the cost of hospitalization. In order to minimize costs and decrease hospitalizations, counseling on modifiable risk factors contributing to AF has been strongly emphasized. With the release of novel oral anticoagulants bypassing the need for anticoagulant bridging or laboratory monitoring, post-discharge nurse-led home intervention, and novel methods of heart rate monitoring, home-based AF management has reached a new level of ease and sophistication. In this review, we aimed to review modifiable risk factors for AF and various methods of home-based management of AF, along with their benefits.

show abstract

Characteristics and 2‐year outcomes of dabigatran treatment in patients with heart failure and atrial fibrillation: GLORIA‐AF

Dubner¹,

Teutsch

Huisman

et al. 2020

ESC Heart Failure

View full text Add to dashboard Cite

Aims This study aimed to describe baseline characteristics of patients with atrial fibrillation (AF) at risk of stroke with and without history of heart failure (HF) and report 2-year outcomes in the dabigatran-treated subset of a prospective, global, observational study (GLORIA-AF). Methods and results Newly diagnosed patients with AF and CHA 2 DS 2-VASc score ≥ 1 were consecutively enrolled. Baseline characteristics were assessed by the presence or absence of HF diagnosis at enrolment. Incidence rates for outcomes in dabigatran-treated patients were estimated with and without standardization by stroke (excluding HF component) and bleeding risk scores. A total of 15 308 eligible patients were enrolled, including 15 154 with known HF status; of these, 3679 (24.0%) had been diagnosed with HF, 11 475 (75.0%) had not. Among 4873 dabigatran-treated patients, 1169 (24.0%) had HF, and 3658 (75.1%) did not; the risk of stroke was high (CHA 2 DS 2-VASc score ≥ 2) for 94.3% of patients with HF and 85.8% without, while 6.0% and 7.0%, respectively, had a high bleeding risk (HAS-BLED ≥ 3). Incidence rates of all-cause death in dabigatran-treated patients with and without HF, standardized for CHA 2 DS 2-VASc and HAS-BLED scores, were 4.76 vs. 1.80 per 100 patient years (py), with roughly comparable rates of stroke (0.82 vs. 0.60 per 100 py) and major bleeding (1.20 vs. 0.92 per 100 py). Conclusions Patients with AF and history of HF may have greater disease burden at AF diagnosis and increased mortality rates vs. patients without HF. Stroke and major bleeding rates were roughly comparable between groups confirming the long-term safety and effectiveness of dabigatran in patients with HF.

show abstract

Atrial Fibrillation and Heart Failure: Update 2015

Cited by 50 publications

References 114 publications

Rosuvastatin reduces the recurrence rate following catheter ablation for atrial fibrillation in patients with heart failure

Rosuvastatin reduces the recurrence rate following catheter ablation for atrial fibrillation in patients with heart failure

Evaluating the benefits of home-based management of atrial fibrillation: current perspectives

Characteristics and 2‐year outcomes of dabigatran treatment in patients with heart failure and atrial fibrillation: GLORIA‐AF

Contact Info

Product

Resources

About